Home › Research › Health systems and care delivery
Initiating second-line antidiabetic medication among older adults with type 2 diabetes on Metformin
Kristen DeCarlo, Amisha Wallia, Raymond H. Kang, Andrew Cooper, Manisha Cherupally, Sterling A. Harris, Cassandra Aikman, David T. Liss et al.. BMC Geriatrics, 2022-02-03
Topic: Risk, prevention and care in population studies
Over half of participants (54%) received SFU as initial second-line ADM, 14% received BI, and 32% received another ADM. In multivariable models, the odds of filling SFU or BI was higher for participants in poor health than those in good or intermediate health [OR 1.13 (95% CI 1.05-1.21) and OR 2.34 (95% CI 2.14-2.55), respectively]. SFU and BI were also more commonly filled by older adults with poor glycemic control. Despite clinical consensus to use caution prescribing SFU and BI among older adults in poor health, these medications remain frequently used in this particularly vulnerable population.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
DeCarlo, K., Wallia, A., Kang, R. H., Cooper, A., Cherupally, M., Harris, S. A., et al. (2022). Initiating second-line antidiabetic medication among older adults with type 2 diabetes on Metformin. BMC Geriatrics. https://doi.org/10.1186/s12877-022-02792-3
Vancouver
DeCarlo K, Wallia A, Kang RH, Cooper A, Cherupally M, Harris SA, et al. Initiating second-line antidiabetic medication among older adults with type 2 diabetes on Metformin. BMC Geriatrics. 2022. doi:10.1186/s12877-022-02792-3. PMID: 35114955.
BibTeX
@article{decarlo2022-35114955,
author = {DeCarlo, Kristen and Wallia, Amisha and Kang, Raymond H. and Cooper, Andrew and Cherupally, Manisha and Harris, Sterling A. and Aikman, Cassandra and Liss, David T. and others},
title = {{Initiating second-line antidiabetic medication among older adults with type 2 diabetes on Metformin}},
journal = {BMC Geriatrics},
year = {2022},
doi = {10.1186/s12877-022-02792-3},
pmid = {35114955},
url = {https://doi.org/10.1186/s12877-022-02792-3}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
Key findings
- Over half of participants (54%) received SFU as initial second-line ADM, 14% received BI, and 32% received another ADM.
- In multivariable models, the odds of filling SFU or BI was higher for participants in poor health than those in good or intermediate health [OR 1.13 (95% CI 1.05-1.21) and OR 2.34 (95% CI 2.14-2.55), respectively].
- SFU and BI were also more commonly filled by older adults with poor glycemic control.
- Despite clinical consensus to use caution prescribing SFU and BI among older adults in poor health, these medications remain frequently used in this particularly vulnerable population.
Why it matters
This study examined which second-line diabetes medications older adults with type 2 diabetes started and found that medications requiring caution in frail patients were still commonly used. It provides no information about treating, curing, or preventing Alzheimer's disease.
Study details
- Effect sizeOR 1.13 (95% CI 1.05-1.21); OR 2.34 (95% CI 2.14-2.55)
- Evidence strengthLow
How this study scored 40/100
Published in a peer-reviewed journal. Scored zero for study design, sample size, studied in people and randomised / blinded because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (BMC Geriatrics) |
| Journal's citation record | 2 / 4 | BMC Geriatrics: journal h-index 153 (OpenAlex, 2026-10-29) |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 3 / 5 | 2022 — within 6 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 3 / 3 | Effect reported with a statistic (interval, p-value, ratio or similar) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomised / blinded | 0 / 2 | No randomisation or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 2 / 7 | Cited 7 times (OpenAlex, 2026-10-10) |
| Citations per year | 1 / 5 | 1.2 citations a year over 6 year(s) since 2022 |
| Impact for its field and year | 2 / 6 | Cited 1.1× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 0 / 6 | No other study in this library cites it |
| Still being cited | 0 / 4 | Cited 1 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 2 / 4 | Last-listed author Matthew James O’Brien: h-index 25 (OpenAlex, whole career) |
| Institution's track record | 2 / 3 | Northwestern University: institution h-index 1,592 (OpenAlex) |
| Multi-centre collaboration | 1 / 3 | OpenAlex lists 2 institution(s) in 1 country |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 35114955) |
| Free to read | 2 / 2 | Free to read |
| Total | 40 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here.
Related studies in Health systems and care delivery
Also tagged “delirium”
858 studies in the library carry the topic tag “delirium”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 858 tagged studies.